首页> 外文期刊>Seminars in Hematology >The Epigenetic Basis of Diffuse Large B-Cell Lymphoma
【24h】

The Epigenetic Basis of Diffuse Large B-Cell Lymphoma

机译:弥漫性大B细胞淋巴瘤的表观遗传基础

获取原文
获取原文并翻译 | 示例
       

摘要

The pathogenesis of diffuse large B-cell lymphoma (DLBCL) is strongly linked to perturbation of epigenetic mechanisms. The germinal center (GC) B cells from which DLBCLs arise are prone to instability in their cytosine methylation patterns. DLBCLs inherit this epigenetic instability and display variable degrees of epigenetic heterogeneity. Greater epigenetic heterogeneity is linked with poor clinical outcome. Somatic mutations of histone-modifying proteins have also emerged as a hallmark of DLBCL. The effect of these somatic mutations may be to disrupt epigenetic switches that control the GC phenotype and "lock in" certain oncogenic features of GC B cells, resulting in malignant transformation. DNA methyltransferase and histone methyltransferase inhibitors are emerging as viable therapeutic approaches to erase aberrant epigenetic programming, suppress DLBCL growth, and overcome chemotherapy resistance. This review will discuss these recent advances and their therapeutic implications. (C) 2015 Elsevier Inc. All rights reserved.
机译:弥漫性大B细胞淋巴瘤(DLBCL)的发病机制与表观遗传机制的扰动密切相关。产生DLBCL的生发中心(GC)B细胞的胞嘧啶甲基化模式容易不稳定。 DLBCL继承了这种表观遗传不稳定性,并显示出不同程度的表观遗传异质性。表观遗传学上的异质性更高与临床结果差有关。组蛋白修饰蛋白的体细胞突变也已成为DLBCL的标志。这些体细胞突变的作用可能是破坏控制GC表型的表观遗传开关,并“锁定” GC B细胞的某些致癌特征,从而导致恶性转化。 DNA甲基转移酶和组蛋白甲基转移酶抑制剂正在成为可行的治疗方法,以消除异常的表观遗传程序,抑制DLBCL的生长,并克服化疗耐药性。本文将讨论这些最新进展及其治疗意义。 (C)2015 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号